BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26067860)

  • 1. The Glasgow Prognostic Score Determined During Concurrent Chemoradiotherapy Is an Independent Predictor of Survival for Cervical Cancer.
    Nishida T; Nakamura K; Haraga J; Ogawa C; Kusumoto T; Seki N; Masuyama H; Katayama N; Kanazawa S; Hiramatsu Y
    Int J Gynecol Cancer; 2015 Sep; 25(7):1306-14. PubMed ID: 26067860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
    Hu K; Wang W; Liu X; Meng Q; Zhang F
    Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
    Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
    Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
    Tian T; Gao X; Ju Y; Ding X; Ai Y
    Arch Gynecol Obstet; 2021 Mar; 303(3):793-801. PubMed ID: 33009996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
    Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
    Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes: a single institution retrospective review.
    Ng BH; Rozita A; Adlinda A; Lee WC; Wan Zamaniah W
    Asian Pac J Cancer Prev; 2015; 16(9):3827-33. PubMed ID: 25987044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Mean Apparent Diffusion Coefficient Is Significantly Correlated With Event-Free Survival in Patients With International Federation of Gynecology and Obstetrics Stage Ib to IIIb Cervical Cancer.
    Himoto Y; Fujimoto K; Kido A; Baba T; Tanaka S; Morisawa N; Koyasu S; Konishi I; Togashi K
    Int J Gynecol Cancer; 2015 Jul; 25(6):1079-85. PubMed ID: 25853385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
    Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
    Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
    Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.